Rightway vs Pfizer

Side-by-side comparison of AI visibility scores, market position, and capabilities

Pfizer leads in AI visibility (93 vs 53)
Rightway logo

Rightway

ChallengerHealthcare

Care Navigation & Pharmacy Benefits Management

Rightway is the most transparent PBM and care navigation platform for employers; delivers 16.1% lower pharmacy costs and 15% medical cost savings; launched 2025 rebrand as integrated PBM + care navigation leader.

AI VisibilityBeta
Overall Score
C53
Category Rank
#225 of 596
AI Consensus
87%
Trend
stable
Per Platform
ChatGPT
57
Perplexity
54
Gemini
51

About

Rightway is a healthcare benefits company that combines Pharmacy Benefits Management (PBM) and personalized care navigation in a single integrated platform for self-insured employers. Founded in 2017 and headquartered in New York City, Rightway positions itself as the most transparent and member-focused PBM in the market — operating on fully aligned, pass-through pricing with a 100% transparency model and a total pharmacy spend guarantee that traditional PBMs do not offer. The company launched a significant 2025 rebrand marking its evolution from challenger to category leader.

Full profile
Pfizer logo

Pfizer

LeaderHealthcare Tech

Enterprise

Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.

AI VisibilityBeta
Overall Score
A93
Category Rank
#1 of 596
AI Consensus
80%
Trend
stable
Per Platform
ChatGPT
94
Perplexity
89
Gemini
94

About

Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.

Full profile

AI Visibility Head-to-Head

53
Overall Score
93
#225
Category Rank
#1
87
AI Consensus
80
stable
Trend
stable
57
ChatGPT
94
54
Perplexity
89
51
Gemini
94
54
Claude
92
54
Grok
98

Key Details

Category
Care Navigation & Pharmacy Benefits Management
Enterprise
Tier
Challenger
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.